232 related articles for article (PubMed ID: 18048490)
21. Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice.
Cheung C; Yu AM; Chen CS; Krausz KW; Byrd LG; Feigenbaum L; Edwards RJ; Waxman DJ; Gonzalez FJ
J Pharmacol Exp Ther; 2006 Mar; 316(3):1328-34. PubMed ID: 16291874
[TBL] [Abstract][Full Text] [Related]
22. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
[TBL] [Abstract][Full Text] [Related]
23. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
24. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
25. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
26. Expression of cytochromes P450 3A in mouse lung: effects of dexamethasone and pregnenolone 16alpha-carbonitrile.
Haag M; Fautrel A; Guillouzo A; Frossard N; Pons F
Arch Toxicol; 2003 Mar; 77(3):145-9. PubMed ID: 12632254
[TBL] [Abstract][Full Text] [Related]
27. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
28. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
29. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
30. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
Galetin A; Houston JB
J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
[TBL] [Abstract][Full Text] [Related]
31. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
[TBL] [Abstract][Full Text] [Related]
32. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY
Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383
[TBL] [Abstract][Full Text] [Related]
33. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
34. Inhibition kinetics of monoclonal antibodies against cytochromes P450.
Mei Q; Tang C; Lin Y; Rushmore TH; Shou M
Drug Metab Dispos; 2002 Jun; 30(6):701-8. PubMed ID: 12019198
[TBL] [Abstract][Full Text] [Related]
35. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.
Charles KA; Rivory LP; Brown SL; Liddle C; Clarke SJ; Robertson GR
Clin Cancer Res; 2006 Dec; 12(24):7492-7. PubMed ID: 17189422
[TBL] [Abstract][Full Text] [Related]
37. [Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities].
Niwa T
Yakugaku Zasshi; 2024; 144(2):197-202. PubMed ID: 38296497
[TBL] [Abstract][Full Text] [Related]
38. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
39. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6.
Jones BC; Hyland R; Ackland M; Tyman CA; Smith DA
Drug Metab Dispos; 1998 Sep; 26(9):875-82. PubMed ID: 9733666
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
Yamazaki H; Nakajima M; Nakamura M; Asahi S; Shimada N; Gillam EM; Guengerich FP; Shimada T; Yokoi T
Drug Metab Dispos; 1999 Sep; 27(9):999-1004. PubMed ID: 10460798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
